The results of an Interregional quality assurance scheme for tests in the diagnosis of megaloblastic anaemia were reviewed to assess the methods used. Serum folate assays showed great variation between methods, partly due to limitations in assessment by external quality assurance. Red cell folate assays yielded widely different results and much imprecision due both to the differences in preparation of the haemolysate and to the problems inherent in radioassay of a mixture of folate compounds. Intrinsic factor antibody tests showed appreciable variation in sensitivity. There was considerable inconsistence in the detection of polymorph nuclear hypersegmentation.
Regional trials in haematology provide laboratories with external quality assurance. We have organised a scheme for vitamin assays for some years,' adding two other tests more recently. The number of participants, however, permits not only an assessment of individual performance but also of the methods in use. The results of the trial give an indication of current practice.
TRIALS Vitamin assays
Two samples are issued 11 times yearly for serum vitamin B12 and folate assays with a whole blood specimen in CPD-adenine for red cell folate assays. An arbitrary haematocrit of 0 45 and serum folate of 1-0 gg/l were given with the whole blood sample. A full evaluation of even only two or three requires much time, has usually to be limited to only a few different batches, and will show the method under the most ideal conditions. The results from quality assurance schemes can supplement kit assessments, indicating the performance over a period of time in a variety of laboratories. Radioisotope assays of vitamin B12 assays have improved considerably since our previous review. 1 The most important change has been in their relative accuracy. The differences between kits has narrowed, and the mean produced by all participants can now be taken as close to the "true" value, as determined by the chosen reference method, when normal sera are assayed. It would be unwise to assume that the convergence of means would also apply at lower levels, though all kits used in the trials in the past four years differentiate pernicious anaemia sera from normal. A comparison of many methods11 showed that all were capable of distinguishing normal from abnormal sera, providing that the user's own reference range was considered.
The secondary reference serum preparation, which will be checked periodically against the British primary standard, is now available to all trial participants. We would encourage any laboratory to produce its own normal serum pool, standardised against the secondary perparation. The relative accuracy of red cell folates is most different with Amersham. This kit gave the highest results. The use of sodium ascorbate instead of ascorbic acid distinguishes the haemolysate preparation of this kit from the others. At its pH both haemolysis and deconjugation will be incomplete, and conditions at the binding stage will favour affinity for polyglutamates if these are still present. The concentration of folate7 12 and the incubation time of the haemolysate7 12 affect the results with some kits. The estimation of red cell folate is of greater clinical value than that of serum folate"3 and the need for a red cell folate standard is evident.
The Wellcome immunoassay quality control programme issued an advisory note concerning the higher vitamin B12 and serum folate results with the Becton Dickinson solid phase kit. Our results agree with it but show that it may not apply to the solid phase no-boil kit for vitamin B12 and red cell folates. Most manufacturers recommend that kit users should determine their own reference intervals, but differences in interpretation of some results with Becton Dickinson kits suggest that this is not universally done.
The results of IFA tests show that strong antibodies and normal sera are correctly diagnosed by all methods. The tests using commercial reagents are superior to the in-house procedures in the detection of weak antibodies. The method ofGottlieb et al,3 which does not allow for the effect of serum binding, gave the lowest incidence of positive results. We have not tested specificity.
Most laboratories undertake assessment of polymorph nuclear segmentation. The two trials we carried out show that there is appreciable discrepancy. There is evidently difficulty in deciding what may con-stitute discrete lobes or what the reference range is, or both. At a subsequent meeting trial participants were asked to count the lobes of a nucleus shown in a projected transparency. The responses varied from three to eight, with two thirds agreeing on six lobes. Although not a specific finding for vitamin deficiency, hypersegmentation is of high sensitivity in patients with megaloblastic anaemia,`4 and an increase in segmentation may occur with a fall in the serum vitamin B 12 even before the dU suppression test becomes abnormal. 15 The trials show that if the assessment is to be generally useful more familiarity with normal films and what constitutes an individual lobe seem to be required.
